A recent study in a murine NASH model demonstrated that antibodies targeting OPN not only attenuated fibrosis but also inflammation, suggesting that targeting OPN in the early stages of NAFLD may be effective in preventing the progression to NASH and fibrosis [21]. Here, SPP1 is linked to metabolic dysfunction-associated steatohepatitis.